Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|June 6, 2013
Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcomeKarin Boslooper, Robby Kibbelaar, Huib Storm, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 26, 2023
Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathyBerdien E Oortgiesen, Marloes Dekens, Ruud Stapel, et al.
Journal of Cancer Survivorship : Research and Practice|September 17, 2024
Health care utilization up to 11 years after diagnosis among patients with a hematologic malignancy and its association with socioeconomic positionAfke Ekels, Lonneke V van de Poll-Franse, Djamila E Issa, et al.
Cancer Epidemiology|May 3, 2017
No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic statusKarin Boslooper, Mels Hoogendoorn, Eric N van Roon, et al.
British Journal of Haematology|April 24, 2014
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort studyAndre Wieringa, Karin Boslooper, Mels Hoogendoorn, et al.
European Journal of Haematology|September 21, 2023
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient populationCamille Kockerols, Peter J M Valk, Nicole M A Blijlevens, et al.
Histopathology|July 22, 2017
MYC expression and translocation analyses in low-grade and transformed follicular lymphomaSietse M Aukema, Roel van Pel, Inga Nagel, et al.
Blood Advances|December 16, 2018
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLLArnon P Kater, Sabina Kersting, Yvette van Norden, et al.
Haematologica|October 2, 2025
Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO studyDina Nienke Lokhorst, Yolba Smit, Bart J F Van den Bemt, et al.
Journal of Medical Internet Research|December 14, 2021
Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled TrialSimone Oerlemans, Lindy Paulina Johanna Arts, Jacobien M Kieffer, et al.
Pageof 7